Literature DB >> 24758887

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study.

Clive A Kelly1, Vadivelu Saravanan2, Mohamed Nisar2, Subha Arthanari2, Felix A Woodhead2, Alec N Price-Forbes2, Julie Dawson2, Navtej Sathi2, Yasmeen Ahmad2, Gouri Koduri2, Adam Young2.   

Abstract

OBJECTIVES: The prevalence of interstitial lung disease (ILD) in RA is ∼5%. Previous work identified increasing age, active articular disease and articular damage as risk factors for RA-associated ILD (RA-ILD). The roles of high-resolution CT (HRCT) and lung function testing in defining the nature and extent of pulmonary involvement have recently been explored. This study is the first to examine predictive and prognostic factors for the development of RA-ILD and to report on the physiological and radiological characteristics of the condition from a large multicentre UK network.
METHODS: We collected data from centres across the UK on patients with both RA and ILD (proved on HRCT) diagnosed over a 25-year period from 1987 to 2012 using a standard pro forma. Potential predictors of RA-ILD were analysed. Baseline lung function data were recorded and related to HRCT findings. We analysed HRCT for subtype and extent of lung involved and examined the relationship between these and both all-cause and pulmonary mortality. We compared our results with case controls matched for age and gender using computer-generated selection from the RA population from one contributing centre.
RESULTS: A total of 230 patients were identified from across the UK with proven RA-ILD diagnosed over 25 years. Median age at diagnosis was 64 years and the male:female ratio was 1:1.09. Univariate analysis showed anti-CCP antibody titres to be the single most strongly associated predictor of RA-ILD. Male gender, age at onset, smoking and RF were all independently associated with RA-ILD on multivariate analysis. Vital capacity (VC) was preserved in limited disease but reduced in extensive disease, while gas transfer was reduced in both. Usual interstitial pneumonia (UIP) was the most common subtype on HRCT and both this and extensive disease were associated with increased all-cause mortality.
CONCLUSION: This is the largest study of RA-ILD in the UK. Anti-CCP antibodies were strongly associated with RA-ILD in both sexes. Smoking was strongly associated with ILD in males, which may explain the higher frequency of RA-ILD in men. The predominant HRCT pattern was UIP and most patients had limited disease at presentation. The presence of UIP and extensive disease are associated with increased mortality. Baseline gas transfer is a useful screening tool for ILD, while the preservation of VC at baseline might predict limited disease on HRCT.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  high-resolution computed tomography; lung disease; prognosis; pulmonary function; rheumatoid arthritis; risk factors

Mesh:

Substances:

Year:  2014        PMID: 24758887     DOI: 10.1093/rheumatology/keu165

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  123 in total

Review 1.  Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions.

Authors:  Jürgen Braun; Klaus Krüger; Bernhard Manger; Matthias Schneider; Christof Specker; Hans Joachim Trappe
Journal:  Dtsch Arztebl Int       Date:  2017-03-24       Impact factor: 5.594

2.  Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists.

Authors:  Sarah Geerts; Wim Wuyts; Ellen De Langhe; Jan Lenaerts; Jonas Yserbyt
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Yongfeng Zhang; Hongbin Li; Nawei Wu; Xin Dong; Yi Zheng
Journal:  Clin Rheumatol       Date:  2017-02-12       Impact factor: 2.980

Review 4.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

5.  Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis.

Authors:  Bryant R England; Punyasha Roul; Tina D Mahajan; Namrata Singh; Fang Yu; Harlan Sayles; Grant W Cannon; Brian C Sauer; Joshua F Baker; Jeffrey R Curtis; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

6.  Risk factors for progression and prognosis of rheumatoid arthritis-associated interstitial lung disease: single center study with a large sample of Chinese population.

Authors:  Qiang Fu; Li Wang; Luling Li; Yifan Li; Ran Liu; Yi Zheng
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

Review 7.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

8.  Telomere length and genetic variant associations with interstitial lung disease progression and survival.

Authors:  Chad A Newton; Justin M Oldham; Brett Ley; Vikram Anand; Ayodeji Adegunsoye; Gabrielle Liu; Kiran Batra; Jose Torrealba; Julia Kozlitina; Craig Glazer; Mary E Strek; Paul J Wolters; Imre Noth; Christine Kim Garcia
Journal:  Eur Respir J       Date:  2019-04-11       Impact factor: 16.671

9.  Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.

Authors:  Chase S Correia; Melissa R Briones; Rong Guo; Rochella A Ostrowski
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

10.  Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Elizabeth F Redente; Martin A Aguilar; Bart P Black; Benjamin L Edelman; Ali N Bahadur; Stephen M Humphries; David A Lynch; Lutz Wollin; David W H Riches
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.